Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.

Dapagliflozin delivers cardiometabolic benefits in patients with myocardial infarction, regardless of their baseline A1c ...

The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

Dapagliflozin significantly reduced the risk of all-cause mortality or worsening heart failure by 28% in high-risk patients undergoing transcatheter aortic valve implantation (TAVI).

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

On July 16 2025, the Court of Appeal dismissed AstraZeneca’s appeal and upheld the first instance decision, finding that AstraZeneca’s compound ...

Low, clinically relevant doses of metformin lower blood glucose by inhibiting the Rap1 protein in specific neurons of the ...

In Q1 FY26, Akums reported total income of Rs. 1,051 crore, with healthy Adj EBITDA of Rs. 156 crore reflecting a robust 19.1 ...

The Maryland Prescription Drug Affordability Board (PDAB) found that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) present affordability ...

Akums reports Q1 FY26 total income of Rs. 1,051 crore with 2.4% growth, 19% YoY adjusted EBITDA growth: Our Bureau, Bengaluru Tuesday, August 12, 2025, 15:30 Hrs [IST] Akums Drugs ...